首页 | 本学科首页   官方微博 | 高级检索  
     

雾化吸入舒利迭辅助治疗慢性阻塞性肺病的疗效与抗炎作用的临床观察
引用本文:卢琴华. 雾化吸入舒利迭辅助治疗慢性阻塞性肺病的疗效与抗炎作用的临床观察[J]. 中国医药导报, 2012, 9(17): 103-104,106
作者姓名:卢琴华
作者单位:石家庄市优抚医院内科,河北石家庄,050800
摘    要:目的观察舒利迭治疗慢性阻塞性肺病(COPD)的疗效与抗炎作用,并探讨其作用机制。方法将78例COPD患者按随机、对照、开放原则分为普米克令舒组39例和舒利迭组39例,两组均进行常规治疗,普米克令舒组再给予普米克令舒,舒利迭组再给予舒利迭,均治疗6个月,治疗前后采用肺功能测定仪测定肺功能指标,进行动脉血气分析,测定痰液炎细胞及中性粒细胞计数。结果舒利迭组与普米克令舒组治疗后FEV1、FEV1/FVC、FEV1/预计值、PaO2较治疗前明显升高,痰液炎细胞计数、中性粒细胞分类较治疗前均明显降低,差异有高度统计学意义(P〈0.01);治疗后,舒利迭组FEV1、FEV1/FVC、FEV1/预计值、PaO2较普米克令舒组明显提高,痰液炎细胞计数、中性粒细胞分类均较普米克令舒组明显降低(P〈0.01);舒利迭组的总有效率为94.87%,普米克令舒组的总有效率为79.49%,舒利迭的总有效率显著高于普米克令舒(P〈0.01)。结论舒利迭治疗COPD临床疗效确切,快速消除呼吸道炎症,快速缓解症状与体征,恢复患者肺功能,安全性好,值得临床推广使用。

关 键 词:舒利迭  慢性阻塞性肺病  临床应用

Clinical observation of efficacy and anti-inflammatory effects of aerosol inhalation Seretide in the treatment of COPD
LU Qinhua. Clinical observation of efficacy and anti-inflammatory effects of aerosol inhalation Seretide in the treatment of COPD[J]. China Medical Herald, 2012, 9(17): 103-104,106
Authors:LU Qinhua
Affiliation:LU Qinhua Department of Inner Medicine,Shijiazhuang Special Care Hospital,Hebei Province,Shijiazhuang 050800,China
Abstract:Objective To observe efficacy and anti-inflammatory effects of aerosol inhalation of Seretide in the treatment of COPD,and to investigate its mechanism.Methods 78 COPD patients were randomly divided into Pulmicort Respules group of 39 cases and Seretide group of 39 cases.The two groups were both given conventional treatment,Pulmicort Respules group was given Pulmicort Respules,the Seretide group was given Seretide.Both groups were treated for 6 months.The lung function,arterial blood gas analysis,sputum inflammatory cell and neutrophil count were determined before and after treatment.Results The FEV1,FEV1/FVC ratio,FEV1/predicted value,PaO2 of the Seretide group and Pulmicort Respules group after treatment were significantly higher than before,the sputum inflammatory cell count,neutrophils after treatment were significantly lower than before treatment(P < 0.01).After treatment,the FEV1,FEV1/FVC ratio,FEV1/predicted value,PaO2 of the Seretide group were significantly higher than Pulmicort Respules group,the sputum inflammatory cell count,neutrophils of the Seretide group were significantly lower than Pulmicort Respules group(P < 0.01).The total effective rate of Seretide group was 94.87%,the Pulmicort Respules group was 79.49%,the Seretide group was significantly higher than Pulmicort Respules group.Conclusion The Seretide has exact clinical efficacy in the treatment of COPD,can rapid eliminate respiratory inflammation,rapid relief symptoms and signs,recover lung function,and is safety,which is worthy of clinical use.
Keywords:Seretide  COPD  Clinical application
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号